The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic

• Published in: Current research in pharmacology and drug discovery 2022-01, Vol.3, p.100101-100101, Article 100101
• Main Authors: Kamath, Chethana, Brenner, Erica J
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 2590-2571; 2590-2571
• DOI: 10.1016/j.crphar.2022.100101

Patients with inflammatory bowel disease (IBD) often require the use of immunosuppressant medications that increase infection risk, leading to concerns over the safe use of IBD medications during the Coronavirus 19 (COVID-19) pandemic. To summarize available evidence on the safety and appropriate use of IBD medications during the COVID-19 pandemic, particularly in regard to risk of severe COVID-19 outcomes such as hospitalization, respiratory failure, or death for patients on IBD therapeutics. The majority of IBD medications are safe to continue during the COVID-19 pandemic, with a few notable exceptions. Patients with IBD who do not have COVID-19 should continue their prescribed IBD therapies, although steroids are associated with severe COVID-19 outcomes and should be weaned when possible. Corticosteroids should be tapered and discontinued when possible in patients with IBD who test positive for COVID-19 as well. Patients with IBD who test positive for COVID-19 should hold biologics, thiopurines, methotrexate, and tofacitinib for at least 2 weeks, and those who have symptoms should not restart these medications until symptom resolution. During the COVID-19 pandemic, all patients with IBD should continue to follow public health guidance including social distancing, masking, and COVID-19 vaccination recommendations. •Asymptomatic IBD patients with COVID-19 should hold biologics and certain immunomodulators for at least 2 weeks.•Symptomatic IBD patients with COVID-19 should hold biologics and certain immunomodulators until symptoms are improved.•Corticosteroids should be tapered and discontinued when possible in patients with IBD who test positive for COVID-19.